MAPT and tauopathy: This approach, however, does not lend itself to removing existing intraneuronal pathology, and it is still unclear to what extent seeded aggregation drives disease in different tauopathies.7–9 Other approaches such as proteolyis-targeting chimeras (PROTACs), which recruit ubiquitination machinery to aggregates, have shown potential in degrading tau in cell-based models; however, they also suffer from poor bioavailability and aggregate specificity, as well as complex pharmacodynamics.10,11